Warning: The NCBI web site requires JavaScript to function. more...
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Malmström V, Trollmo C, Klareskog L.
Arthritis Res Ther. 2005;7 Suppl 2:S15-20. Epub 2005 Mar 16. Review.
Related citations
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM, Pope RM.
Arthritis Res Ther. 2005;7 Suppl 2:S21-5. Epub 2005 Mar 16. Review.
Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R, Moilanen E.
Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):276-84. Epub 2009 Feb 18. Review.
Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.
Fiocco U, Sfriso P, Oliviero F, Pagnin E, Scagliori E, Campana C, Dainese S, Cozzi L, Punzi L.
Autoimmun Rev. 2008 Oct;8(1):76-82. Epub 2008 Aug 15. Review.
Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis.
Choy EH.
Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. Review.
T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE.
Bull NYU Hosp Jt Dis. 2010;68(3):162-5. Review.
Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM, Block JA.
Am J Ther. 2008 Jan-Feb;15(1):53-8. Review.
Targeting lymphocyte activation to treat rheumatoid arthritis.
Falgarone G, Semerano L, Rullé S, Boissier MC.
Joint Bone Spine. 2009 Jul;76(4):327-32. Epub 2009 Jun 16. Review.
Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D, Wyss-Coray T, Gallati H, Pichler WJ.
J Immunol. 1995 Jul 1;155(1):118-27.
Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response.
Scarsi M, Ziglioli T, Airò P.
J Rheumatol. 2010 May;37(5):911-6. Epub 2010 Mar 15.
B-cell: a logical target for treatment of rheumatoid arthritis.
Youinou P, Jamin C, Saraux A.
Clin Exp Rheumatol. 2007 Mar-Apr;25(2):318-28. Review.
Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N.
J Dermatolog Treat. 2006;17(4):229-34. Review.
CTLA-4Ig: uses and future directions.
Ben-Shoshan M.
Recent Pat Inflamm Allergy Drug Discov. 2009 Jun;3(2):132-42.
Targeting T cell costimulation in autoimmune disease.
Stuart RW, Racke MK.
Expert Opin Ther Targets. 2002 Jun;6(3):275-89. Review.
[Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
Yasuoka Y, Goto A, Seriu T.
Nihon Yakurigaku Zasshi. 2011 Feb;137(2):87-94. Review. Japanese. No abstract available.
[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].
Dejaco C, Duftner C, Wipfler E, Schirmer M.
Wien Med Wochenschr. 2009;159(3-4):70-5. Review. German.
[Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
Harigai M.
Clin Calcium. 2007 Apr;17(4):577-84. Review. Japanese.
Abatacept in the treatment of rheumatoid arthritis.
Buch MH, Vital EM, Emery P.
Arthritis Res Ther. 2008;10 Suppl 1:S5. Epub 2008 Oct 15. Review.
Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis.
Lundquist L.
Adv Ther. 2007 Mar-Apr;24(2):333-45. Review.
New therapeutics that treat rheumatoid arthritis by blocking T-cell activation.
MacKenzie NM.
Drug Discov Today. 2006 Oct;11(19-20):952-6. Epub 2006 Sep 7. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on